Medical Oncologist
Targeted therapy in AML
Targeted Therapy in AML — Which Mutations Are Tested and What They Mean
Whether targeted therapy plays a role in your AML treatment depends on specific mutations found in your bone marrow cells — established by molecular testing, not by the AML diagnosis alone.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Mutation first, drug second — A targeted drug works only against the mutation it was designed to block. Testing tells you which, if any, apply to your case.
- Multiple mutations tested at once — A single bone marrow sample is screened for a panel of mutations, not one at a time.
- Results take one to two weeks — Treatment planning cannot begin properly until molecular results are back. Ask your team when to expect them.
- A negative result is still useful — Not finding a targetable mutation guides your team toward the treatments that do apply to your cancer.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy in AML uses drugs designed to block specific mutations that drive your cancer. Not all AML has a targetable mutation. Your bone marrow sample is tested for mutations such as FLT3, IDH1 and IDH2 before your oncologist can say whether a targeted drug applies to your case.
Which mutations are tested in AML, and what targeted options exist for each
FLT3 mutation
FLT3 mutations come in two forms: FLT3-ITD and FLT3-TKD. NCCN recommends adding a FLT3 inhibitor to standard induction chemotherapy in newly diagnosed FLT3-mutated AML. Midostaurin and quizartinib (for FLT3-ITD) are among the options listed for this setting. For relapsed or refractory FLT3-mutated AML, gilteritinib is FDA-approved and NCCN-recommended.
IDH1 mutation
Ivosidenib is an IDH1 inhibitor approved by the FDA for IDH1-mutated AML. It is used in relapsed or refractory disease. It is also used in newly diagnosed older adults who cannot tolerate intensive chemotherapy, either alone or combined with azacitidine. Availability in India is subject to CDSCO approval — ask your oncologist what is accessible.
IDH2 mutation
IDH2 mutations have been a target for specific IDH2 inhibitors in relapsed or refractory AML. Approvals and availability for this mutation class in India may differ from Western markets. Your oncologist will tell you what options are currently accessible for IDH2-mutated AML.
BCL-2 pathway — venetoclax
Venetoclax targets BCL-2, a protein that helps AML cells survive. It does not require a specific mutation to be prescribed. It is approved combined with azacitidine or low-dose cytarabine for newly diagnosed AML in adults who are older or unable to tolerate intensive chemotherapy.
TP53, NPM1, CEBPA and other mutations
Your panel will also screen for TP53, NPM1, CEBPA, RUNX1 and other mutations. No established targeted drug exists for most of these in AML. They do influence prognosis, treatment intensity and eligibility for clinical trials. A TP53 mutation, for example, affects which regimens are likely to work and whether a trial may be the better path.
How does molecular testing work in AML?
Molecular testing is done on the bone marrow sample taken during your diagnostic biopsy. In most cases, the same sample is used for the diagnosis and the mutation panel — you do not need a second procedure.
The laboratory extracts DNA from the leukemic cells and sequences it to identify mutations. Results typically take one to two weeks, though specialised tests can take longer.
Your oncologist combines those results with your age, fitness, cytogenetics and whether this is newly diagnosed or relapsed AML to build your treatment plan.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What happens when your AML has a targetable mutation?
Finding a mutation such as FLT3 or IDH1 opens an additional treatment option. It does not automatically mean targeted therapy replaces everything else.
In newly diagnosed AML, a targeted drug is often added to standard induction chemotherapy rather than replacing it. In relapsed or refractory disease, a targeted agent may be used alone or in combination, depending on previous treatment and current fitness.
Ask your oncologist specifically what the mutation result means for your plan — which drug applies, what it is intended to achieve, and how it fits alongside any other treatment.
What if no targetable mutation is found in your AML?
Most AML treatment does not depend on a targetable mutation. Standard intensive chemotherapy, or lower-intensity regimens such as venetoclax combinations for those who cannot tolerate intensive treatment, remain effective approaches across many mutation profiles.
A negative panel is not a closed door. It tells your team which pathway is driving your AML and helps them select the treatments most likely to work for you.
If you are interested in clinical trials, a complete mutation profile is often required to match you to a study. Ask your oncologist whether a trial is appropriate given your result.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the difference between FLT3-ITD and FLT3-TKD?
Both are mutations in the FLT3 gene, but they occur at different locations and behave somewhat differently. According to NCCN, FLT3-ITD has been associated with a higher risk of relapse in the absence of targeted treatment. Both variants are addressed in current NCCN guidance for AML. Your molecular report will specify which is present, and your oncologist will explain how that affects the choice of FLT3 inhibitor.
Can you have both an IDH1 and an IDH2 mutation at the same time?
It is unusual to have both simultaneously, and they are treated as separate findings. IDH1 and IDH2 are different genes, and their inhibitors are not interchangeable — a drug approved for IDH1-mutated AML will not work against an IDH2 mutation. Your molecular report will say which, if either, is present. If neither is found, this pathway is not currently targetable for your AML.
Does venetoclax only work for older patients with AML?
The approved use of venetoclax with azacitidine or low-dose cytarabine covers AML in adults who are not candidates for intensive induction chemotherapy — this is often, though not always, an older age group. Whether it applies to you depends on a fitness assessment rather than age alone. Your oncologist will evaluate this using performance status and organ function, not a birthday.
How long will it take to get my molecular test results back?
Most molecular panels take one to two weeks from when the sample reaches the laboratory. Specialised tests can take a little longer. If your AML is progressing rapidly, your oncologist may begin treatment before the full panel is back and adjust the plan when results arrive. Ask your team for an expected date so you are not waiting without a timeline.
Is targeted therapy for AML available at CION?
CION administers AML treatment, including targeted agents, across its network of centres as day care and inpatient care. Drug availability in India is governed by CDSCO approval and supply, which may differ from what is approved in the United States or Europe. Your oncologist will tell you which agents are currently accessible for your mutation profile and whether a trial is an option if a particular drug is not available locally. CION does not provide CAR-T or cell therapy.
If my AML has a TP53 mutation, are there any targeted options?
TP53-mutated AML is one of the harder settings to treat. As of current NCCN guidance, there is no established targeted drug approved specifically for this mutation in AML. Clinical trials are actively studying agents that aim to address TP53-driven disease. Your oncologist can tell you whether a trial is open for which you may be eligible, and which regimens are appropriate for your situation. We do not yet have a proven targeted option for this outside of trials.